Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
about
Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.ESR1 and endocrine therapy resistance: more than just mutations.Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations.BRCA1/2 testing: therapeutic implications for breast cancer managementMulticenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
P2860
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@en
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@nl
type
label
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@en
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@nl
prefLabel
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@en
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@nl
P2093
P2860
P50
P1476
Diverse BRCA1 and BRCA2 Revers ...... tant Breast or Ovarian Cancer.
@en
P2093
Carol Aghajanian
Charlotte Fribbens
David M Hyman
Ino de Bruijn
Isaac García-Murillas
Iñaki Comino-Méndez
Jane L Meisel
Jason Konner
Laetitia Borsu
P2860
P304
P356
10.1158/1078-0432.CCR-17-0544
P407
P577
2017-08-01T00:00:00Z